In addition, CPT1A appears to be a candidate therapeutic target in various cancers, including lung cancer, breast cancer, etc., (Ma et al., 2024; Altea-Manzano et al., 2023; Tang et al., 2022). This evidence concerns the gene CPT1A and lung cancer.